Loading...

MREO MEREO BIOPHARMA GROUP PLC Operational Disruptions 8-K Filing

MR B

MR

MEREO BIOPHARMA GROUP PLC

(MREO)

2024 8-K

Director Resignation

Financial Results Announced

Delisting Notification

Clinical Study Results

Q3 Financial Results

Product Expansion

Financial Statements

Financial Results

Clinical Update

License Agreement Update

Q2 Financial Results

Underwriting Agreement

Interim Data from Phase 2/3...

Financial Results Announcement

Extension Agreement with Ru...

Financial Results Announcement

External Links:

Mereo Biopharma Group Plc and Ultragenyx Pharmaceutical Inc. announced positive interim data from the Phase 2 portion of the Phase 2/3 Orbit study, showing significant reduction in fractures and improvements in bone mineral density in patients with OI.

AI Assistant

MEREO BIOPHARMA GROUP PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.